Thomas Tray Biography and Net Worth

Insider of Incyte


Thomas Tray is the VP of Fin., Chief Accounting Officer & Controller at Incyte.

What is Thomas Tray's net worth?

The estimated net worth of Thomas Tray is at least $1.68 million as of September 12th, 2024. Mr. Tray owns 24,825 shares of Incyte stock worth more than $1,675,439 as of October 6th. This net worth approximation does not reflect any other assets that Mr. Tray may own. Learn More about Thomas Tray's net worth.

How old is Thomas Tray?

Mr. Tray is currently 46 years old. There are 8 older executives and no younger executives at Incyte. The oldest executive at Incyte is Ms. Pamela M. Murphy, Vice President of Investor Relations & Corporate Communications, who is 73 years old. Learn More on Thomas Tray's age.

How do I contact Thomas Tray?

The corporate mailing address for Mr. Tray and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Thomas Tray's contact information.

Has Thomas Tray been buying or selling shares of Incyte?

Thomas Tray has not been actively trading shares of Incyte during the past quarter. Most recently, Thomas Tray sold 572 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a transaction totalling $36,001.68. Following the completion of the sale, the insider now directly owns 24,825 shares of the company's stock, valued at $1,562,485.50. Learn More on Thomas Tray's trading history.

Who are Incyte's active insiders?

Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.

Are insiders buying or selling shares of Incyte?

During the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 55,171 shares worth more than $3,494,605.05. The most recent insider tranaction occured on September, 12th when insider Thomas Tray sold 572 shares worth more than $36,001.68. Insiders at Incyte own 17.5% of the company. Learn More about insider trades at Incyte.

Information on this page was last updated on 9/12/2024.

Thomas Tray Insider Trading History at Incyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/12/2024Sell572$62.94$36,001.6824,825View SEC Filing Icon  
6/6/2024Sell1,093$58.91$64,388.6321,634View SEC Filing Icon  
12/12/2023Sell210$57.36$12,045.6024,503View SEC Filing Icon  
12/19/2022Sell1,223$82.16$100,481.6816,606View SEC Filing Icon  
7/22/2022Sell1,564$83.13$130,015.3217,702View SEC Filing Icon  
See Full Table

Thomas Tray Buying and Selling Activity at Incyte

This chart shows Thomas Tray's buying and selling at Incyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incyte Company Overview

Incyte logo
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $67.49
Low: $66.45
High: $67.56

50 Day Range

MA: $64.33
Low: $60.29
High: $68.59

2 Week Range

Now: $67.49
Low: $50.27
High: $70.36

Volume

1,236,688 shs

Average Volume

2,423,910 shs

Market Capitalization

$15.15 billion

P/E Ratio

20.45

Dividend Yield

N/A

Beta

0.73